|
시장보고서
상품코드
2052238
전신 마취제 시장 : 약물 분자별, 투여 경로별, 최종사용자별, 지역별General Anesthesia Drugs Market, By Drug molecule, By Route of Administration, By End User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
전신 마취제 시장은 2026년에 55억 9,000만 달러로 추정되며, 2033년까지 75억 1,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.3%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 55억 9,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 4.30% | 2033년 시장 규모 예측: | 75억 1,000만 달러 |
전신 마취제는 전신마취에 사용되는 주요 약물군 중 하나입니다. 전신 마취제는 폐암, 천식 등 호흡기질환, 선천성 심장병, 심근경색 등 심장질환, 발작, 파킨슨병 등 신경질환, 심한 화상, 외상성 뇌손상 등 다양한 질환에 투여됩니다. 또한, 가슴성형이나 코수술 등 미용 목적의 수술에서도 전신마취를 하는 경우가 있습니다.
시장 역학
마취제 연구 및 개발(R&D)에 대한 자금 투입 증가는 예측 기간 동안 전신 마취제 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 지난 8월 세인트루이스 워싱턴대학교 의과대학과 미시간대학교 연구진은 환자중심성과연구기관(PCORI)으로부터 3,300만 달러의 연구비를 지원받아 정맥 프로포폴과 흡입 마취제를 비교하여 어느 마취제가 환자의 회복을 더 잘 돕고 임상적 결과를 개선하는지 알아보고자 환자의 회복 경험을 더 좋게 하고 임상 결과를 개선하는지를 밝히는 연구를 진행했습니다.
제품 회수는 예측 기간 동안 전신 마취제 시장의 성장을 억제할 것으로 예상됩니다. 예를 들어, 2022년 5월 호스피라사는 제품 표시 오류로 인해 주사제 병원용 마취제인 부피바카인 염산염과 리도카인 염산염을 각각 1로트씩 회수한다고 발표했습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 세계 전신 마취제 시장의 주요 기업 프로파일을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 전신 마취제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 전신 마취제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 전신 마취제 시장 : 약제 분자별, 2021-2033년
제5장 세계의 전신 마취제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 전신 마취제 시장 : 최종사용자별, 2021-2033년
제7장 세계의 전신 마취제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.06.16General Anesthesia Drugs Market is estimated to be valued at USD 5.59 Bn in 2026 and is expected to reach USD 7.51 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.59 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.30% | 2033 Value Projection: | USD 7.51 Bn |
General anesthetics is one of the major classes of drugs used for general anesthesia. General anesthetics can be administered for a number of medical conditions including but not limited to the following: respiratory problems, such as lung cancer and asthma; cardiac problems, such as congenital heart disease and myocardial infarction; neurological disorders, such as seizures and Parkinson's disease; severe burns and traumatic brain injury. General anesthesia can also be given for cosmetic reasons, such as breast augmentation and nose surgery.
Market Dynamics
Increasing funding for R&D in anesthetic drugs is expected to propel growth of the general anesthesia drugs market over the forecast period. For instance, in August 2022, researchers at Washington University School of Medicine in St. Louis and the University of Michigan received a US$ 33 million grant from the Patient-Centered Outcomes Research Institute to compare intravenous propofol to inhaled anesthetic drugs to determine which of the common anesthetic drugs offers better patient recovery experiences and improved clinical outcomes.
Product recall is expected to limit growth of the general anesthesia drugs market over the forecast period. For instance, in May 2022, Hospira announced to recall one lot each of the injectable hospital anesthetics bupivacaine HCL and lidocaine HCL due to mislabeling of product.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global general anesthesia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Hospira Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global general anesthesia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global general anesthesia drugs market
Detailed Segmentation
- Global General Anesthesia Drugs Market, By Molecule Type (Revenue, USD Bn, 2021 - 2033)
- Propofol
- Sevoflurane
- Dexmedetomidine
- Desflurane
- Remifentanil
- Midazolam
- Global General Anesthesia Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Baxter Healthcare
- Dr. Reddy's Laboratories
- Fresenius KabiPfizer Inc.
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals
- Teva Pharmaceuticals
- Par Pharmaceutical
- Viatris Inc.
- AbbVie
- Piramal Critical Care
- Aspen Global Incorporated
- B. Braun SE
- Abbott
- COSMO PHARMACEUTICALS
- Hospira Inc.
- Maruishi
- Hengrui
- Lunan
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Molecule
- Market Snippet, By Route of Administration
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Development
- Pipeline Analysis
- Distribution Channel Analysis
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global General Anesthesia Drug Market , By Drug Molecule, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Desflurane
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Isoflurane
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Propofol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Etomidate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Methoexital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Hiopentone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Midazolam
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Ketamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
5. Global General Anesthesia Drug Market , By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Intravenous Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Inhalation Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
6. Global General Anesthesia Drug Market , By End User, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global General Anesthesia Drug Market , By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Baxter Healthcare
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Reddy's Laboratories
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hospira
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Maruishi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hengrui
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Lunan
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fresenius Kabi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hikma Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sagent Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Par Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Viatris Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Piramal Critical Care
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Aspen Global Incorporated
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- B. Braun SE
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Abbott
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cosmo pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Baxter Healthcare
9. Section
- References
- Research Methodology
- About us and Sales Contact
